Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics Limited has announced a proposed non-renounceable pro rata issue of up to 214,315,640 new ordinary fully paid shares, alongside a separate placement or other type of issue of up to 89,080,864 shares, as part of a broader capital-raising initiative. The staged timetable, with key dates spanning late December 2025 to late January 2026, signals a substantial expansion of the company’s equity base, which may provide additional funding capacity for its therapeutic programs while diluting existing holdings, and underscores management’s reliance on the equity markets to support ongoing development and growth plans.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is an ASX-listed biotechnology company focused on developing therapeutic treatments, operating within the broader pharmaceuticals and life sciences sector. Its ordinary fully paid shares trade under the ticker NUZ on the Australian Securities Exchange.
Average Trading Volume: 817,788
Technical Sentiment Signal: Sell
Current Market Cap: A$58.82M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.